Sutro Biopharma, Inc.

NasdaqGM:STRO Stock Report

Market Cap: US$150.1m

Sutro Biopharma Future Growth

Future criteria checks 1/6

Sutro Biopharma's earnings are forecast to decline at 6.5% per annum while its annual revenue is expected to grow at 17.7% per year. EPS is expected to grow by 4.1% per annum.

Key information

-6.5%

Earnings growth rate

4.1%

EPS growth rate

Biotechs earnings growth27.5%
Revenue growth rate17.7%
Future return on equityn/a
Analyst coverage

Good

Last updated19 Dec 2024

Recent future growth updates

Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results

Aug 16
Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results

Recent updates

Why Investors Shouldn't Be Surprised By Sutro Biopharma, Inc.'s (NASDAQ:STRO) 26% Share Price Plunge

Nov 30
Why Investors Shouldn't Be Surprised By Sutro Biopharma, Inc.'s (NASDAQ:STRO) 26% Share Price Plunge

Revenues Working Against Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Following 25% Dive

Oct 11
Revenues Working Against Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Following 25% Dive

Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology

Sep 23

There's No Escaping Sutro Biopharma, Inc.'s (NASDAQ:STRO) Muted Revenues Despite A 29% Share Price Rise

Aug 24
There's No Escaping Sutro Biopharma, Inc.'s (NASDAQ:STRO) Muted Revenues Despite A 29% Share Price Rise

Brokers Are Upgrading Their Views On Sutro Biopharma, Inc. (NASDAQ:STRO) With These New Forecasts

Aug 22
Brokers Are Upgrading Their Views On Sutro Biopharma, Inc. (NASDAQ:STRO) With These New Forecasts

Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results

Aug 16
Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results

The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%

Jun 26
The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%

We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right

May 31
We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right

Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates

Apr 02
Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates

The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet

Mar 28
The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet

Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%

Dec 19
Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%

Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?

Aug 24
Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?

Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?

Feb 10
Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?

An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued

Jan 12
An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued

Sutro Biopharma: Partnership Progress Warrants Exposure

Aug 16

New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)

Aug 11
New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)

Sutro Biopharma GAAP EPS of -$0.55, revenue of $28.1M

Aug 08

Sutro to get $10M payment from Merck after first patient dosed in collaboration trial

Jul 26

Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?

May 02
Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?

Sutro; A Biotech To Watch With A Catalyst Rapidly Approaching

Dec 27

Is Sutro Biopharma (NASDAQ:STRO) A Risky Investment?

Dec 26
Is Sutro Biopharma (NASDAQ:STRO) A Risky Investment?

Sutro Biopharma initiated buy at H.C. Wainwright citing ADC candidates

Jun 18

Earnings and Revenue Growth Forecasts

NasdaqGM:STRO - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202646-321-210-2989
12/31/202549-297-236-29411
12/31/202459-224-192-20611
9/30/2024161-124-109-106N/A
6/30/2024169-124-78-75N/A
3/31/2024154-115-119-115N/A
12/31/2023154-107-116-112N/A
9/30/202349-172-156-150N/A
6/30/202357-143-57-50N/A
3/31/202375-130-29-22N/A
12/31/202268-119-44N/A
9/30/202270-123-16N/A
6/30/202253-134-96-84N/A
3/31/202253-114-101-87N/A
12/31/202162-106-97-82N/A
9/30/202160-127-93-79N/A
6/30/202169-79-85-72N/A
3/31/202150-43-88-79N/A
12/31/202043-32-75-68N/A
9/30/20204613-70-62N/A
6/30/202040-17-66-61N/A
3/31/202041-61-68-64N/A
12/31/201943-56-69-65N/A
9/30/201951-42-60-58N/A
6/30/201946-4046N/A
3/31/201941-3868N/A
12/31/201838-351113N/A
9/30/201823-491214N/A
6/30/201833-40N/A-36N/A
3/31/201842-30N/A-37N/A
12/31/201752-20N/A-37N/A
12/31/201660N/AN/A-13N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: STRO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: STRO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: STRO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: STRO's revenue (17.7% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: STRO's revenue (17.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if STRO's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 11:33
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sutro Biopharma, Inc. is covered by 15 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhiqiang ShuBerenberg
Tazeen AhmadBofA Global Research
Thomas ShraderBTIG